Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Epirus Biopharmaceuticals Inc    EPRSQ

EPIRUS BIOPHARMACEUTICALS INC (EPRSQ)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Bulletin Board - Othe…
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
0.007(c) 0(c) 0.0042(c) 0.0041(c) 0.0042(c) Last
20 150 18 111 287 9 425 119 491 Volume
-100.00% -2.38% +2.44% Change
More quotes
Company
EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business.It focuses on biosimilars, which are biologic drugs that are demonstrated to be highly similar to a previously approved biologic drug, known as a reference... 
More about the company
Latest news on EPIRUS BIOPHARMACEUTICALS
2016EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars ..
GL
2016EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financi..
GL
2016EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Fina..
GL
2016EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for..
GL
2016EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare..
GL
2016J&J, AbbVie Shares Drop on Potential Drug Competition
DJ
2016EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global He..
GL
2015EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Inflixi..
GL
2015EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Prov..
GL
2015EPIRUS Biopharmaceuticals Reschedules Its Third Quarter 2015 Financial Result..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Biotechnology & Medical Research - NEC
Chart EPIRUS BIOPHARMACEUTICALS
Duration : Period :
Epirus Biopharmaceuticals  Technical Analysis Chart | EPRSQ | US29428P1075 | 4-Traders
Income Statement Evolution
Sector and Competitors
1st jan.Capitalization (M$)
EPIRUS BIOPHARMACEUTICALS INC46.43%0
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227